Alerts will be sent to your verified email
Verify Email
KOBO
|
Kobo Biotech
|
Zyden Gentec
|
Fabino Enterprises
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-1.77 % | -24.76 % | 0.76 % |
|
5yr Avg Net Profit Margin
|
-3.79 % | -137.59 % | 0.54 % |
|
Price to Book
|
0.0 | n/a | 0.0 |
|
P/E
|
0.0 | n/a | 89.51 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 785.76 Days | 59.85 Days |
|
5yr Average Interest Coverage Ratio
|
0.99 | -2.08 | 5.69 |
|
5yr Avg ROCE
|
11.79 % | -6.92 % | 1.29 % |
|
5yr Avg Operating Profit Margin
|
8.83 % | -95.87 % | 1.24 % |
|
5 yr average Debt to Equity
|
1.62 | 0.68 | 0.14 |
|
5yr CAGR Net Profit
|
n/a | -1.66 % | -4.36 % |
|
5yr Average Return on Assets
|
-0.89 % | -15.88 % | 0.49 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
44.95 % | 0.0 | 56.82 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -17.28 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kobo Biotech
|
Zyden Gentec
|
Fabino Enterprises
|
|---|